Pluhar G Elizabeth, Pennell Christopher A, Olin Michael R
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN. 55108.
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN. 55445.
Crit Rev Immunol. 2015;35(2):153-72. doi: 10.1615/critrevimmunol.2015013607.
Despite the growing number of preclinical and clinical trials focused on immunotherapy for the treatment of malignant gliomas, the prognosis for this disease remains grim. Cancer immunotherapy seeks to recruit an effective immune response to eliminate tumor cells. To date, cancer vaccines have shown only limited effectiveness because of our incomplete understanding of the necessary effector cells and mechanisms that yield efficient tumor clearance. CD8+ T cell cytotoxic activity has long been proposed as the primary effector function necessary for tumor regression. However, there is increasing evidence that indicates that components of the immune system other than CD8+ T cells play important roles in tumor eradication and control. The following review should provide an understanding of the mechanisms involved in an effective antitumor response to guide future therapeutic designs. The information provided suggests an alternate means of effective tumor clearance in malignant glioma to the canonical CD8+ cytotoxic T cell mechanism.
尽管针对恶性胶质瘤免疫治疗的临床前和临床试验数量不断增加,但该疾病的预后仍然严峻。癌症免疫疗法旨在激发有效的免疫反应以消除肿瘤细胞。迄今为止,由于我们对产生有效肿瘤清除的必要效应细胞和机制了解不完整,癌症疫苗仅显示出有限的有效性。长期以来,CD8 + T细胞的细胞毒性活性一直被认为是肿瘤消退所必需的主要效应功能。然而,越来越多的证据表明,除CD8 + T细胞外,免疫系统的其他成分在肿瘤根除和控制中也发挥着重要作用。以下综述应有助于理解有效抗肿瘤反应所涉及的机制,以指导未来的治疗设计。所提供的信息表明,除了经典的CD8 + 细胞毒性T细胞机制外,还有另一种有效的恶性胶质瘤肿瘤清除方法。